A previous study [92] has reported that in leukemia, mutant SRSF2 cells were more sensitive to E71079, a splicing-altering compound that binds to the SF3B complex, than wild-type SRSF2 cells [93, 94]. This evidence concerns the gene SRSF2 and leukemia.